Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Adult stem cell therapy for no-option refractory disabling angina - Lisata Therapeutics; CD34+ autologous stem cell therapy - Lisata Therapeutics/Takeda; CD34+ cell therapy - Lisata Therapeutics/Takeda; CLBS14; CLBS14-NORDA; CLBS14-RfA; OLOGO

Latest Information Update: 26 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baxter Healthcare Corporation
  • Developer Lisata Therapeutics; Takeda
  • Class Haematopoietic stem cells therapies; Stem cell therapies
  • Mechanism of Action Angiogenesis inducing agents; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Angina pectoris; Peripheral vascular disorders

Most Recent Events

  • 26 Sep 2022 No development reported - Phase-III for Angina pectoris in USA (Intracardiac)
  • 14 Sep 2022 Cend Therapeutics has merged with Caladrius Biosciences to form Lisata Therapeutics
  • 05 Aug 2021 CLBS 14 is available for licensing as of 05 Aug 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top